(Q35614159)

9 August 2017

1 reference

title

Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma (English)

1 reference

9 August 2017

Lodovico Balducci

1

1 reference

9 August 2017

Lazzaro Repetto

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

100

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

6-11

1 reference

Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Aging and cancer in America. Demographic and epidemiologic perspectives

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

The economics of febrile neutropenia: implications for the use of colony-stimulating factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

The Nature of Adverse Events in Hospitalized Patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Use of growth factors in the elderly patient with cancer: a report from the Second International Society for Geriatric Oncology (SIOG) 2001 meeting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11861

7 January 2021

Identifiers

DOI

10.1002/CNCR.11861

1 reference

9 August 2017

1 reference